Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.

Dykes C, Wu H, Sims M, Holden-Wiltse J, Demeter LM.

J Clin Microbiol. 2010 Nov;48(11):4035-43. doi: 10.1128/JCM.00605-10. Epub 2010 Sep 8.

3.

The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.

Wang J, Liang H, Bacheler L, Wu H, Deriziotis K, Demeter LM, Dykes C.

Virology. 2010 Jul 5;402(2):228-37. doi: 10.1016/j.virol.2010.03.018. Epub 2010 Apr 18.

4.

Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.

Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.

Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.

5.

Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1.

Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC.

J Virol. 2009 Aug;83(16):8289-92. doi: 10.1128/JVI.00709-09. Epub 2009 May 27.

6.

Real-time PCR analysis of HIV-1 replication post-entry events.

Mbisa JL, Delviks-Frankenberry KA, Thomas JA, Gorelick RJ, Pathak VK.

Methods Mol Biol. 2009;485:55-72. doi: 10.1007/978-1-59745-170-3_5.

PMID:
19020818
7.

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.

Takeuchi Y, McClure MO, Pizzato M.

J Virol. 2008 Dec;82(24):12585-8. doi: 10.1128/JVI.01726-08. Epub 2008 Oct 8.

8.
9.

HIV-1 drug-resistance and drug-dependence.

Baldwin C, Berkhout B.

Retrovirology. 2007 Oct 25;4:78. Review.

10.

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.

Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G.

PLoS Pathog. 2006 Nov;2(11):e119.

11.

Rationale and uses of a public HIV drug-resistance database.

Shafer RW.

J Infect Dis. 2006 Sep 15;194 Suppl 1:S51-8. Review.

12.

Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Dykes C, Wang J, Jin X, Planelles V, An DS, Tallo A, Huang Y, Wu H, Demeter LM.

J Clin Microbiol. 2006 Jun;44(6):1930-43. Erratum in: J Clin Microbiol. 2007 Jun;45(6):2102.

15.

Acceptor RNA cleavage profile supports an invasion mechanism for HIV-1 minus strand transfer.

Chen Y, Balakrishnan M, Roques BP, Bambara RA.

J Biol Chem. 2005 Apr 15;280(15):14443-52. Epub 2005 Jan 18.

16.
17.

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B.

J Virol. 2004 Nov;78(22):12428-37.

18.

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, Li Q, Pham P, Cofrancesco J, Persaud D, Siliciano RF.

J Virol. 2004 Feb;78(4):1718-29.

19.

Steps of the acceptor invasion mechanism for HIV-1 minus strand strong stop transfer.

Chen Y, Balakrishnan M, Roques BP, Bambara RA.

J Biol Chem. 2003 Oct 3;278(40):38368-75. Epub 2003 Jul 22.

20.

Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.

Menzo S, Monachetti A, Balotta C, Corvasce S, Rusconi S, Paolucci S, Baldanti F, Bagnarelli P, Clementi M.

AIDS. 2003 Mar 28;17(5):663-71.

PMID:
12646788

Supplemental Content

Support Center